Published in Oncologist on July 23, 2013
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (neo-TN) | NCT01057069
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS One (2015) 1.48
BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. Mol Cell (2014) 1.14
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget (2014) 1.05
'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res (2014) 0.96
YAP regulates S-phase entry in endothelial cells. PLoS One (2015) 0.89
Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Res (2014) 0.85
The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol (2013) 0.82
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med (2014) 0.81
A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair. Nucleic Acids Res (2014) 0.78
Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. ACS Chem Biol (2015) 0.78
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. Fam Cancer (2016) 0.77
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther (2017) 0.76
Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget (2016) 0.75
Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract (2016) 0.75
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. PLoS One (2016) 0.75
TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Breast and ovarian cancer. N Engl J Med (2003) 3.84
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
The genetics of breast cancer susceptibility. Annu Rev Genet (1998) 2.21
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene (1999) 2.09
Synthetic lethality--a new direction in cancer-drug development. N Engl J Med (2009) 1.84
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res (2012) 1.81
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res (2009) 1.77
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene (1998) 1.74
Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci (2001) 1.57
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis (2000) 1.46
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet (2002) 1.35
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer (1995) 1.34
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 1.33
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle (2006) 1.32
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene (2001) 1.32
Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res (2003) 1.27
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene (2001) 1.18
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol (2010) 1.15
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol (2012) 1.04
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat (2010) 1.02
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer (2011) 1.01
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res (2006) 0.95
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res (2004) 0.89
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer (2001) 0.86
The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol (2011) 0.85
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem (2009) 0.84
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res (2010) 0.83
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat (2003) 0.82
BRCA2 promoter hypermethylation in sporadic breast cancer. OMICS (2012) 0.77
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 1.97
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol (2009) 1.67
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer (2005) 1.65
Ultra-sensitive detection of rare T cell clones. J Immunol Methods (2011) 1.64
Diagnosing and treating breast cancer in elderly women: a call for improved understanding. J Am Geriatr Soc (2007) 1.43
Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol (2004) 1.16
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer (2006) 1.05
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer (2008) 1.02
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol (2010) 0.92
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol (2004) 0.90
Management strategies for controlling endemic and seasonal mouse parvovirus infection in a barrier facility. Lab Anim (NY) (2011) 0.89
T1 N0 triple negative breast cancer: a bad actor. Breast J (2009) 0.75